drugset
drugset / Trial / NCT05679050

Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer

NCT05679050 ↗

Phase 2 Unknown 30 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

Based on the safety and benefit of neoadjuvant therapy for patients with pancreatic cancer in the available evidence, as well as the principle of sequential chemotherapy with different regimens and the existing preliminary investigation , the aim of this study was to further explore the efficacy and safety of neoadjuvant therapy with AG regimen followed by FOLFIRINOX regimen in patients with resectable pancreatic cancer, and to assess the impact of neoadjuvant therapy on the health-related quality of life of patients, in order to bring new treatment options for neoadjuvant therapy of pancreatic cancer.

Timeline

Start
2022-10-01
Primary completion
2024-10-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1 g Intravenous
Subject Irinotecan Small molecule 150 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 125 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 65 mg/m2 Intravenous
Subject Tetrahydrofolate Small molecule 400 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

pancreatic exocrine neoplasm